Esmya FDA Approval Status

FDA Approved: No
Brand name: Esmya
Generic name: ulipristal acetate
Company: Allergan plc
Treatment for: Uterine Fibroids

Esmya (ulipristal acetate) is an oral selective progesterone receptor modulator (SPRM) in development for the treatment of uterine fibroids.

Development timeline for Esmya

Date	Article
Aug 21, 2018	Allergan Receives Complete Response Letter from the U.S. Food and Drug Administration for Ulipristal Acetate New Drug Application
Feb 28, 2018	Allergan Announces FDA Has Extended The Ulipristal Acetate NDA Review Period To August 2018
Oct 10, 2017	Allergan Announces that the FDA Accepts New Drug Application for Ulipristal Acetate for Uterine Fibroids

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.